SOPHiA Genetics and AstraZeneca Expand Ovarian Cancer Testing Program

SOPHiA Genetics, a cloud-native software company and a leader in data-driven medicine, has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country.
 
The expansion of the program, supported by AstraZeneca Spain and its network throughout the country, aims to make this vital testing available to thousands more patients in the country.

Origins of the Collaborative Program

The program from SOPHiA Genetics and AstraZeneca Spain started in 2022, when AstraZeneca and SOPHiA Genetics collaborated to deploy HRD testing to five labs throughout the country. This collaboration allowed for over 4,000 samples to be analyzed to-date, equating to approximately 90 percent of HRD testing available for patients in Spain.
 
With today’s announcement, AstraZeneca Spain named SOPHiA Genetics its preferred partner in deploying HRD testing throughout Spain. Together, SOPHiA Genetics and AstraZeneca are offering the option for HRD testing to become available to even more laboratories throughout the country to help facilitate in-house HRD detection.
 
The testing will not only aid in identifying HRD-positive tumors but is also designed to support faster diagnostics by increasing the volume and speed of next-generation sequencing (NGS) testing and tumor profiling available. By deploying the SOPHiA DDM Platform across further labs, the companies aim to increase accelerated diagnostics for patients and support clinicians in precision treatment planning.

Improving the Approach to Cancer Patients

Marta Moreno, director of Corporate Affairs and Market Access of AstraZeneca Spain, said: “At AstraZeneca we are focused on putting the medicine precision available to patients collaborating with hospitals and reference centers throughout Spain. Thanks to the study of biomarkers we can improve the approach to cancer patients, giving them treatment with greater guarantee of effectiveness and as personalized as possible, complying with our goal of chronicling cancer and getting rid of it someday as a cause of death. Hence our agreement with SOPHiA Genetics, to offer hospital centers throughout Spain the possibility of making an accurate diagnosis for patients with ovarian cancer.”
 
“The ability for local facilities in Spain to test for HRD status is paramount to providers in the region developing data-driven treatment plans to help increase positive health outcomes,” added Kevin Puylaert, Managing Director, EMEA, SOPHiA Genetics. “We are excited to expand our testing program across several local diagnostic facilities. This program will not only make a difference to those who receive testing but will increase the volume of global data on HRD to help further progress on treatment options for those facing ovarian cancer.”